Home Halogens Acetic acid, [[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride (1:1)

Acetic acid, [[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride (1:1)

CAS No.:
121524-09-2
Catalog Number:
AG00158H
Molecular Formula:
C22H27Cl2NO4
Molecular Weight:
440.3601
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$118
- +
5mg
≥98%
1 week
United States
$194
- +
10mg
≥98%
1 week
United States
$301
- +
Product Description
Catalog Number:
AG00158H
Chemical Name:
Acetic acid, [[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride (1:1)
CAS Number:
121524-09-2
Molecular Formula:
C22H27Cl2NO4
Molecular Weight:
440.3601
MDL Number:
MFCD00886563
IUPAC Name:
ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydrochloride
InChI:
InChI=1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1
InChI Key:
NQIZCDQCNYCVAS-RQBPZYBGSA-N
SMILES:
CCOC(=O)COc1ccc2c(c1)C[C@H](CC2)NC[C@@H](c1cccc(c1)Cl)O.Cl
UNII:
N910CJ679E
Properties
Complexity:
491  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
439.132g/mol
Formal Charge:
0
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
440.361g/mol
Monoisotopic Mass:
439.132g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
67.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Noradrenergic activity regulated dexamethasone-induced increase of 5-HT₃ receptor-mediated glutamate release in the rat's prelimbic cortex. Biochimica et biophysica acta 20121201
The beta3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20101001
GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors. Molecular and cellular endocrinology 20100830
Evaluation of the role of superoxide anions in endotoxin-induced impairment of beta-adrenoceptor-mediated vasodilation in equine digital veins. American journal of veterinary research 20100701
Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behavioural brain research 20100120
Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. Experimental physiology 20090401
Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience 20081002
The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080901
Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety. Journal of medicinal chemistry 20080814
Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, biochemistry, and behavior 20080601
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080201
Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs? European journal of pharmacology 20071114
Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice. European journal of pharmacology 20060104
Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. Journal of the American College of Cardiology 20050719
Beta-adrenoceptor-mediated vascular relaxation in spontaneously hypertensive rats. Autonomic neuroscience : basic & clinical 20050331
Beta3-adrenoceptors: relaxant function and mRNA detection in smooth muscle cells isolated from the human colon. Canadian journal of physiology and pharmacology 20040701
beta3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovascular research 20030801
Evaluation of beta3-adrenoceptor-mediated relaxation in intact and endotoxin-treated equine digital veins. American journal of veterinary research 20030601
SR 58611A: SR 58611. Drugs in R&D 20030101
Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. British journal of pharmacology 20020901
Effect of SR 58611A, a beta-3 receptor agonist, against experimental gastro-duodenal ulcers. Indian journal of physiology and pharmacology 20020101
Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. European journal of clinical investigation 20010801
Beta(3)-adrenoceptors control Cl(-) conductance in rabbit nasal epithelium. European journal of pharmacology 20010622
Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists. European journal of pharmacology 20010216
Involvement of beta1- and beta2- but not beta3-adrenoceptor activation in adrenergic PYY secretion from the isolated colon. The Journal of endocrinology 20010101
Peripheral cardiovascular actions of SR 58611 A, a beta 3-adrenoceptor agonist, in the dog: lack of central effect. Fundamental & clinical pharmacology 19990101
SR59230A blocks beta3-adrenoceptor-linked modulation of upcoupling protein-1 and leptin in rat brown adipocytes. European journal of pharmacology 19980703
Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Molecular pharmacology 19960101
Properties